Resumen de Investigación

Analyzed using Evidence Intelligence™

Empagliflozin improves glycemic control in HNF1A-MODY

Última actualización 12 de julio de 2026

Key finding

Empagliflozin lowered the mean glucose level 2.3 mmol/L (95% CI 1.3 to 3.3; P = 0.0001).

The study evaluated the effects of empagliflozin on glycemic control in adults with HNF1A-MODY, finding significant reductions in glucose levels and improvements in time in range.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Short-Term (≤3 mo)

Risk of bias

Some Concerns

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

The study evaluated the effects of empagliflozin on glycemic control in adults with HNF1A-MODY, finding significant reductions in glucose levels and improvements in time in range.

Clinical relevance

These findings are significant as they suggest that empagliflozin could be a valuable treatment option for adults with HNF1A-MODY, a rare form of diabetes. Improved glycemic control can lead to better long-term health outcomes, reducing the risk of diabetes-related complications. This study provides evidence that supports the use of empagliflozin in this specific population, potentially enhancing their quality of life.

Keep in mind

The study's sample size and generalizability may be limited due to the specific population. Potential unmeasured confounders could affect the outcomes. Effectiveness claims are based on statistical significance without assessing long-term clinical implications.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Henrik M, Stine OH, Johanne SJ, et al. Empagliflozin Improves Glycemic Control in Adults with HNF1A-MODY. Diabetes Care. 2026;49(7):1166-1174. doi:10.2337/dc25-2572

View DOI View on PubMed View on PMC

Efectos Principales

Empagliflozin lowered mean glucose levels by 2.3 mmol/L (P = 0.0001).

Time in range increased by 26% with empagliflozin compared to placebo (P = 0.0001).

Fasting plasma glucose decreased by 2.1 mmol/L (P = 0.0005).

Body weight decreased by 0.7 kg (P = 0.0016).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Empagliflozin and Body weight, Fasting Plasma Glucose (FPG), Hypoglycemia events, and 2 more.

This study contributes evidence to

Intervention

Empagliflozin

Outcome

Body weight

Evidence topic

Glycemic Control

Primary intervention

Empagliflozin

Primary outcomes

Body weight
Fasting Plasma Glucose (FPG)
Hypoglycemia events

Evidence topics

Glycemic Control Weight Loss SGLT2 Inhibitors

Primary intervention

Empagliflozin

Primary outcomes

Body weight Fasting Plasma Glucose (FPG)Hypoglycemia events

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

Why it is useful

Contributes to 5 evidence relationships
Includes primary outcome data
Linked to 3 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

SGLT2 Inhibitors and Body Weight

Evidencia relacionada

Relación de evidencia

SGLT2 Inhibitors and Hypoglycemia

Guardar evidencia

Relación de evidencia

SGLT2 Inhibitors and CGM Time in Range

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

Body weight

Empagliflozin → Body weight

Evidence Intelligence™

EvidenceScore™: Strong; Score 79 · Based on 3 studies
ImpactScore™: 83; Positive
ConsistencyScore™: 100; consistent

Based on 3 studies

Add to Evidence Tracker

Fasting Plasma Glucose (FPG)

Empagliflozin → Fasting Plasma Glucose (FPG)

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Hypoglycemia events

Empagliflozin → Hypoglycemia events

Evidence Intelligence™

EvidenceScore™: 64; Moderate
ImpactScore™: 52; Neutral
ConsistencyScore™: 100; consistent

Based on 2 studies

Add to Evidence Tracker

Pre-meal mean glucose

Empagliflozin → Pre-meal mean glucose

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Time in range

Empagliflozin → Time in range

Evidence Intelligence™

EvidenceScore™: 64; Moderate
ImpactScore™: 79; Positive
ConsistencyScore™: 100; consistent

Based on 2 studies

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

La Evidencia Sugiere

Empagliflozin reduced mean glucose levels by 2.3 mmol/L.
Time in range improved by 26% with empagliflozin.
Fasting plasma glucose decreased by 2.1 mmol/L.

A quién se aplica

Adults diagnosed with HNF1A-MODY.
Individuals seeking improved glycemic control.

Tener en Cuenta

Results may not be applicable to other forms of diabetes.
Long-term effects of empagliflozin in this population remain to be studied.
Further research is needed to confirm findings in larger, more diverse populations.

Entre Líneas

The study's sample size and generalizability may be limited due to the specific population.
Potential unmeasured confounders could affect the outcomes.
Effectiveness claims are based on statistical significance without assessing long-term clinical implications.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on SGLT2 Inhibitors and Body Weight, SGLT2 Inhibitors and Hypoglycemia.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Medications

Detailed evidence

SGLT2 Inhibitors → Body Weight

Medications

Evidence Intelligence™

EvidenceScore™: Strong; Score 79 · Based on 3 studies
ImpactScore™: 83; Positive
ConsistencyScore™: 100; consistent

Based on 3 studies

View evidence

Medications

Detailed evidence

SGLT2 Inhibitors → Hypoglycemia

Medications

Evidence Intelligence™

EvidenceScore™: 64; Moderate
ImpactScore™: 52; Neutral
ConsistencyScore™: 100; consistent

Based on 2 studies

View evidence

Incluido en estas colecciones de evidencia

Curated evidence collections and hubs this study is part of.

Body Weight Evidence Hub

All studies measuring Body Weight

3 studies

outcome_hub

Measures Body Weight as a key outcome.

SGLT2 Inhibitors Evidence Hub

All studies on SGLT2 Inhibitors

3 studies

intervention_hub

Contributes to SGLT2 Inhibitors evidence base.

Hypoglycemia Evidence Hub

All studies measuring Hypoglycemia

2 studies

outcome_hub

Measures Hypoglycemia as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Explora más en Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on Empagliflozin and Body weight

Intervention: EmpagliflozinOutcome: Body weight

3 results

All studies on Empagliflozin and Hypoglycemia events

Intervention: EmpagliflozinOutcome: Hypoglycemia events

2 results

All studies on Empagliflozin

Intervention: Empagliflozin

3 results

All studies measuring Body weight

Outcome: Body weight

3 results

All studies measuring Hypoglycemia events

Outcome: Hypoglycemia events

2 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does SGLT2 Inhibitors affect body weight?

Strong Evidence

SGLT2 Inhibitors may improve Body Weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does SGLT2 Inhibitors affect hypoglycemia?

Moderate Evidence

SGLT2 Inhibitors may improve Hypoglycemia.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Hypoglycemia events
EvidenceScore™ Moderate | EvidenceScore™ 64.3 | neutral | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does SGLT2 Inhibitors improve cgm time in range?

Moderate Evidence

SGLT2 Inhibitors appears to improve CGM Time in Range.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Time in range
EvidenceScore™ Moderate | EvidenceScore™ 64.3 | moderate positive | ConsistencyScore™ Consistent | 1 study
2
Pre-meal mean glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does SGLT2 Inhibitors improve fasting glucose?

Moderate Evidence

SGLT2 Inhibitors may improve Fasting Glucose.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Glycemic Control Evidence Hub Weight Loss Evidence Hub SGLT2 Inhibitors Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Empagliflozin and Pre-meal mean glucose All studies on Empagliflozin and Body weight All studies on Empagliflozin and Hypoglycemia events All studies on Empagliflozin and Time in range

Related research

Read related research summaries.

Empagliflozin improves heart function in type 2 diabetes patients Empagliflozin may improve nighttime blood sugar patterns in type 1 diabetes Empagliflozin may reduce kidney disease biomarkers but shows mixed effects on albumin in early diabetes Empagliflozin reduces body fluid volume in type 2 diabetes patients Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetes

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.